Linked Life Data

11763157

Source:http://linkedlifedata.com/resource/pubmed/id/11763157

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2001-12-12
pubmed:abstractText
Clinical and laboratory observations suggest that host immunological responses may occasionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included recombinant cytokines, either alone or in combination with chemotherapeutic regimens or other biological response modifiers, such as vaccines, monoclonal antibodies, dendritic cells and gene therapy. To date, the benefit of these approaches in patients at high-risk of recurrence or advanced disease has been modest. Although many of these novel strategies are limited by weak antigen presentation, tumor-induced tolerance and tumor heterogeneity, it is possible that these approaches will prove more useful when given in combination.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1553-63
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Immunotherapeutic approaches for the treatment of malignant melanoma.
pubmed:affiliation
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. ccuriel@caregroup.harvard.edu
pubmed:publicationType
Journal Article, Review